Physician profile
Michael G Grasso
NPI 1558374983
$16,281.73
in general payments reported to CMS, 2019-2025
55 companies · $2,704 in 2025
The $2,704 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $302 · 2021: $2,214 · 2022: $2,481 · 2023: $3,361 · 2024: $3,386 · 2025: $2,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,432 · Education: $18.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,432.11 |
| Education | $18.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,713.61 | 2019-2025 | |
| Pfizer INC. | $1,613.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,470.51 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,382.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $1,136.12 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $989.44 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $899.75 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $841.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $779.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $472.90 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $352.05 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $316.94 | 2021-2025 | |
| Amarin Pharma, INC. | $254.08 | 2019-2022 | |
| Lundbeck LLC | $253.57 | 2023-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $244.84 | 2023-2024 | Gemtesa |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $238.83 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Astellas Pharma US INC | $236.76 | 2019-2025 | Veozah |
| Abbott Laboratories | $224.76 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $216.94 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $211.31 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Eisai INC. | $209.41 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $198.21 | 2019-2024 | |
| Exact Sciences Corporation | $181.53 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $162.71 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $155.55 | 2024-2025 | Zenpep |
| Esperion Therapeutics, INC. | $154.47 | 2021-2025 | Nexletol |
| Axsome Therapeutics, INC. | $130.41 | 2023-2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $101.36 | 2022 | |
| Dexcom, INC. | $99.28 | 2022-2025 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $87.24 | 2023-2024 | Ibsrela |
| Daiichi Sankyo INC. | $84.49 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $76.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.77 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $56.80 | 2019-2022 | |
| Allergan, INC. | $54.57 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $54.48 | 2019-2025 | Uptravi, Opsumit |
| Xeris Pharmaceuticals, INC. | $52.33 | 2022-2023 | Gvoke Hypopen |
| Medtronic, INC. | $47.82 | 2023-2024 | Linq II, Minimed 770g |
| Shield Therapeutics INC | $45.15 | 2023-2024 | Accrufer |
| Mylan Specialty L.P. | $41.49 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.14 | 2025 | Caplyta |
| Tactile Systems Technology INC | $39.70 | 2025 | Flexitouch Plus, Nimbl |
| Biogen, INC. | $39.31 | 2021-2022 | |
| Alkermes, INC. | $30.19 | 2025 | Vivitrol |
| Sanofi Pasteur INC. | $27.46 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $27.18 | 2024 | Ultomiris |
| Genentech USA, INC. | $26.09 | 2019 | |
| Vanda Pharmaceuticals INC. | $25.86 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.09 | 2022 | |
| Sunovion Pharmaceuticals INC. | $22.91 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.67 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $15.17 | 2021 | |
| Philips North America LLC | $14.20 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.39 | 2023 | |
| Circassia INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Grasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.